BRIEF-Insmed Provides Clinical And Business Update

Reuters12-18 05:03

BRIEF-<a href="https://laohu8.com/S/INSM">Insmed</a> Provides Clinical And Business Update

Dec 17 (Reuters) - Insmed Inc INSM.O:

INSMED PROVIDES CLINICAL AND BUSINESS UPDATE
INSMED INC - PHASE 2B BIRCH STUDY OF BRENSOCATIB IN CRSSNP DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS
INSMED INC - DISCONTINUES CRSSNP PROGRAM
INSMED INC - ACQUIRES PHASE 2 READY MONOCLONAL ANTIBODY FOR POTENTIAL RESPIRATORY AND IMMUNOLOGICAL & INFLAMMATORY INDICATIONS

Source text: ID:nPnyHpg0a

Further company coverage: INSM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592943657?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592943657","market":"us","top_or_hot":-1,"title":"BRIEF-Insmed Provides Clinical And Business Update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/INSM\">Insmed</a> Provides Clinical And Business Update</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Insmed Inc <span>INSM.O</span>:</p><ul><li><p>INSMED PROVIDES CLINICAL AND BUSINESS UPDATE</p></li><li><p>INSMED INC - PHASE 2B BIRCH STUDY OF BRENSOCATIB IN CRSSNP DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS</p></li><li><p>INSMED INC - DISCONTINUES CRSSNP PROGRAM</p></li><li><p>INSMED INC - ACQUIRES PHASE 2 READY MONOCLONAL ANTIBODY FOR POTENTIAL RESPIRATORY AND IMMUNOLOGICAL &amp; INFLAMMATORY INDICATIONS</p></li></ul><p>Source text: <span>ID:nPnyHpg0a</span></p><p>Further company coverage: <span>INSM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Insmed Provides Clinical And Business Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Insmed Provides Clinical And Business Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 05:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/INSM\">Insmed</a> Provides Clinical And Business Update</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Insmed Inc <span>INSM.O</span>:</p><ul><li><p>INSMED PROVIDES CLINICAL AND BUSINESS UPDATE</p></li><li><p>INSMED INC - PHASE 2B BIRCH STUDY OF BRENSOCATIB IN CRSSNP DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS</p></li><li><p>INSMED INC - DISCONTINUES CRSSNP PROGRAM</p></li><li><p>INSMED INC - ACQUIRES PHASE 2 READY MONOCLONAL ANTIBODY FOR POTENTIAL RESPIRATORY AND IMMUNOLOGICAL &amp; INFLAMMATORY INDICATIONS</p></li></ul><p>Source text: <span>ID:nPnyHpg0a</span></p><p>Further company coverage: <span>INSM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUAC694J7:1","article_id":"2592943657","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592943657","pubTimestamp":1766005396,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Insmed Provides Clinical And Business UpdateDec 17 (Reuters) - Insmed Inc INSM.O:INSMED PROVIDES CLINICAL AND BUSINESS UPDATEINSMED INC - PHASE 2B BIRCH STUDY OF BRENSOCATIB IN CRSSNP DID NOT ME","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","INSM":"Insmed"},"translate_title":"简介-Insmed提供临床和业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":0.9},"content_text":"BRIEF-Insmed Provides Clinical And Business UpdateDec 17 (Reuters) - Insmed Inc INSM.O:INSMED PROVIDES CLINICAL AND BUSINESS UPDATEINSMED INC - PHASE 2B BIRCH STUDY OF BRENSOCATIB IN CRSSNP DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTSINSMED INC - DISCONTINUES CRSSNP PROGRAMINSMED INC - ACQUIRES PHASE 2 READY MONOCLONAL ANTIBODY FOR POTENTIAL RESPIRATORY AND IMMUNOLOGICAL & INFLAMMATORY INDICATIONSSource text: ID:nPnyHpg0aFurther company coverage: INSM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592943657","isCrawlerRequest":true}